Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 19.58% | 27.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.58% | 27.02% | |||
| Cost of Revenue | 3.62% | -16.19% | |||
| Gross Profit | 56.32% | 780.09% | |||
| SG&A Expenses | 8.94% | 1.96% | |||
| Depreciation & Amortization | 73.80% | 145.25% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.53% | -10.66% | |||
| Operating Income | 218.15% | 84.39% | |||
| Income Before Tax | 221.69% | -127.45% | |||
| Income Tax Expenses | -168.07% | -17.02% | |||
| Earnings from Continuing Operations | 211.53% | -71.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 211.53% | -71.00% | |||
| EBIT | 218.15% | 84.39% | |||
| EBITDA | 463.09% | 91.92% | |||
| EPS Basic | 205.91% | -70.68% | |||
| Normalized Basic EPS | 258.33% | 87.15% | |||
| EPS Diluted | 193.29% | -70.56% | |||
| Normalized Diluted EPS | 240.39% | 87.15% | |||
| Average Basic Shares Outstanding | 5.32% | 0.16% | |||
| Average Diluted Shares Outstanding | 18.79% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||